{
    "nctId": "NCT02553707",
    "briefTitle": "A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer",
    "officialTitle": "Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Pain; Bone Neoplasms; Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 182,
    "primaryOutcomeMeasure": "Percentage of participants with >=25% reduction in mean pain",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female participants greater than or equal to (\\>=) 18 years of age\n* Breast cancer with bone metastases\n* Pain score of \\>=4 on Worst Pain scale of Brief Pain Inventory (BPI)\n* Stable analgesic regimen.\n\nExclusion Criteria:\n\n* Participants who have received a bisphosphonate within 3 weeks of start of trial\n* Radiotherapy to bone within 4 weeks of enrolment\n* Hypersensitivity to ibandronate\n* Central nervous system (CNS) or meningeal metastases",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}